The Federal Register published notice 2018-28221, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,” and PeptideScanner's exact reviewed identity mapping connects the document to Etelcalcetide.
The Federal Register published notice 2018-28213, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Product-Specific Guidance for Linaclotide; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Linaclotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204669 with status AP dated 2018-12-27, and names octreotide acetate among the application record's active ingredients.
The Federal Register published notice 2018-27805, attributed to FDA and its parent HHS department, on 2018-12-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.
DailyMed lists Structured Product Labeling version 18 for the reviewed Linaclotide label family with a published date of 2018-12-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2018-26289, attributed to FDA and its parent HHS department, on 2018-12-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TRULANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Plecanatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204246 with status AP dated 2018-11-30, and names ganirelix acetate among the application record's active ingredients.
The Federal Register published notice 2018-25950, attributed to FDA and its parent HHS department, on 2018-11-29. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Plecanatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208554 with status AP dated 2018-11-23, and names eptifibatide among the application record's active ingredients.
The Federal Register published notice 2018-25187, attributed to FDA and its parent HHS department, on 2018-11-19. Its official title is “Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
DailyMed lists Structured Product Labeling version 11 for the reviewed Pramlintide label family with a published date of 2018-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 30 for the reviewed Dulaglutide label family with a published date of 2018-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Abaloparatide label family with a published date of 2018-11-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 1 for the reviewed Ziconotide label family with a published date of 2018-10-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2018-22956, attributed to FDA and its parent HHS department, on 2018-10-22. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,” and PeptideScanner's exact reviewed identity mapping connects the document to Abaloparatide.
DailyMed lists Structured Product Labeling version 29 for the reviewed Dulaglutide label family with a published date of 2018-10-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 203765 with status AP dated 2018-09-07, and names octreotide acetate among the application record's active ingredients.
The Federal Register published notice 2018-18614, attributed to FDA and its parent HHS department, on 2018-08-28. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 205054 with status AP dated 2018-08-28, and names leuprolide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 205962 with status AP dated 2018-07-27, and names bivalirudin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 4 for the reviewed Abaloparatide label family with a published date of 2018-07-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.
The official Drugs@FDA dataset lists original submission 1 for ANDA 203258 with status AP dated 2018-07-20, and names eptifibatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091602 with status AP dated 2018-07-16, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091676 with status AP dated 2018-07-13, and names oxytocin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 28 for the reviewed Dulaglutide label family with a published date of 2018-07-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 022517 with status AP dated 2018-06-21, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 205037 with status AP dated 2018-06-05, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 202471 with status AP dated 2018-06-01, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206077 with status AP dated 2018-04-11, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.
The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204693 with status AP dated 2018-03-07, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 6 for the reviewed Lixisenatide label family with a published date of 2018-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.
The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients.